Hyperprolactinémies induites par les antipsychotiques : physiopathologie, clinique et surveillance

Besnard, I.; Auclair, Valérie; Callery, G; Gabriel-Bordenave, C.; Roberge, Claude

doi:10.1016/j.encep.2012.03.002

Cited by 70 publications

(30 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Непродолжительный период наблюдения не позволяет оценить и некоторые клинические эффекты терапии, например восстановление регу-лярного менструального цикла. Кроме того, иссле-дования по коррекции ГАН агонистами дофамино-вых рецепторов часто проводились в очень малых группах, недостаточных для анализа [3,5,11].…”

Section: терапия каберголином гиперпролактинемии ассоциированной с пunclassified

“…В большинстве работ [3,5] указывается, что те-рапия агонистами дофаминовых рецепторов приво-дит к значимому снижению пролактина, однако от-сутствуют сведения, у какой части пациентов дости-гается нормализация пролактина, и чем эти пациен-ты клинически отличаются от остальных. Ни в од-ном исследовании не оценивался уровень пролак-тина и клиническая симптоматика после отмены агонистов дофаминовых рецепторов; следователь-но, неизвестно, насколько долго сохраняется кли-нико-лабораторный эффект.…”

Section: терапия каберголином гиперпролактинемии ассоциированной с пunclassified

See 1 more Smart Citation

Cabergolin therapy of hyperprolactinemia associated with intake of neuroleptics

Yunilainen¹,

Starostina²,

Dzeranova³

et al. 2014

Probl. endokrin.

View full text Add to dashboard Cite

Hyperprolactinemia associated with intake of neuroleptics (HAN) is a commonest endocrine disorder encountered in psychiatric practice. Approaches to the treatment of this condition remain to be developed. It is supposed that the use of dopamine receptor agonists may cause deterioration of the patients' psychic status. We have studied the influence of therapy with cabergolin on 44 patients presenting with HAN. It was shown that the long-term treatment using cabergolin is a safe and efficacious therapeutic modality for the patients suffering from psychic disorders. The frequency of exacerbation of psychic disorders in the group of patients treated with cabergolin was lower than in the control group. It is concluded that the correction of HAN by cabergolin in the patients presenting with psychic disorders leads to the significant improvement of reproductive and sexual functions.

show abstract

Section: терапия каберголином гиперпролактинемии ассоциированной с пunclassified

Cabergolin therapy of hyperprolactinemia associated with intake of neuroleptics

Yunilainen¹,

Starostina²,

Dzeranova³

et al. 2014

Probl. endokrin.

View full text Add to dashboard Cite

show abstract

“…Стабильным оставалось и психическое состоя-ние у 25 женщин с ГАН, получавших бромокриптин в дозах 1,25-8,75 мг в сутки в течение 3 мес [3], а также у 10 больных с ГАН, вызванной рисперидо-ном, которые принимали каберголин в дозе 0,125-0,25 мг в нед в течение 16 нед [11]; на этом фоне у 9 из 10 пациентов отмечалась нормализация уровня пролактина и исчезновение симптомов гиперпро-лактинемии. Аналогичные результаты на неболь-шой выборке (19 больных) были получены и при применении каберголина в тех же дозах в течение 8 нед [5].…”

Section: терапия каберголином гиперпролактинемии ассоциированной с пunclassified

“…У пациентов с ГАН терапия агонистами дофаминовых рецепторов до настоящего времени не нашла широкого примене-* e-mail: olga84j@yandex.ru ния, ввиду вероятности ухудшения психического состояния [3]. Вопрос о том, насколько прием аго-нистов дофаминовых рецепторов негативно влияет на течение психического расстройства, остается от-крытым.…”

unclassified

Cabergolin therapy of hyperprolactinemia associated with intake of neuroleptics

Юнилайнен¹,

Старостина²,

Дзеранова³

et al. 2014

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

show abstract

“…Olanzapine has the main adverse effect of metabolic syndrome, which can increase the risk of diabetes and cardiovascular diseases [6,7]. Risperidone has dose-dependent extrapyramidal effects and causes changes in prolactin concentration, which can leads to disturbances in sexual function such as gynecomastia and galactorrhea [8]. However, the adverse effects of these medicines and their ability to achieve real gains in quality of life require investigation.…”

Section: Introductionmentioning

confidence: 99%

Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users

et al. 2015

View full text Add to dashboard Cite

This cross-sectional study compared quality of life and side effects in 108 users of olanzapine or risperidone suffering schizophrenia and being attended at psychiatric ambulatory services in Rio Grande do Norte, Brazil. Economic, socio-demographic, anthropometric, biochemical, and hormonal variables were compared. The EuroQoL Five-Dimension Scale (EQ-5D) was used to evaluate quality of life, and side effects were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale and the Simpson-Angus Scale. Data were analysed using the χ(2) test and Student's t test, with a significance level of 5 %.The household incomes of approximately 80 % of patients were <2.0 minimum wages ($678). Anthropometric variables (waist circumference, hip circumference, weight, waist-to-hip ratio) and systolic and diastolic blood pressure were noted among male olanzapine users (all p < 0.05). EQ-5D scores showed that olanzapine use significantly impacted self-help ability (p < 0.001). Risperidone users had a mean quality-adjusted life year value of 1. Mean total Simpson-Angus Scale scores was 0.38 for olanzapine users and 0.11 for risperidone users (p < 0.02). Significant differences in UKU were observed for the following items: asthenia/lassitude/fatigue (higher among olanzapine users, p = 0.02), dystonia (higher among olanzapine users, p = 0.01), tremors (higher among olanzapine users, p = 0.03), gynecomastia (higher among risperidone users, p < 0.02), and ejaculatory dysfunction (higher among risperidone users, p < 0.02). Olanzapine users had impaired quality of life, which can be explained in part by adverse motor, biochemical, and hormonal effects characteristic of metabolic syndrome.

show abstract

Hyperprolactinémies induites par les antipsychotiques : physiopathologie, clinique et surveillance

Cited by 70 publications

References 37 publications

Cabergolin therapy of hyperprolactinemia associated with intake of neuroleptics

Cabergolin therapy of hyperprolactinemia associated with intake of neuroleptics

Cabergolin therapy of hyperprolactinemia associated with intake of neuroleptics

Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users

Contact Info

Product

Resources

About